A Phase 2, Single-Arm, Open-label Study of Brentuximab Vedotin in Chinese Patients With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.
- 21 Oct 2016 New trial record